Imagine this: you are a middle-aged man living in Iowa. Your wife has been cooking you dinners of roast pork and potatoes for all the 15 years of your marriage. You're more than a little overweight and your blood pressure is a little high. Suddenly, your firm decides to send you to Bangkok to help a local subsidiary with an important proposal. Off you go, expecting to have a great time. But when your Thai host suggests an evening out on the town to sample the city's notorious nightlife, you start thinking about Viagra.
You're a little embarrassed to see a doctor and you don't know the stuff can be had over the counter in many of the the kingdom's pharmacies, but as luck would have it, you take an afternoon stroll down Sukhumvit Road and spot a little table set up with all sorts of goodies including ... you guessed it ... Viagra. You pocket a pack and later that night head off with your host to the go-go bar. You pop a little blue pill as you walk in the door and 20 minutes later you're on your way to cardiac ICU. The Viagra you so happily bought wasn't Viagra, but a look-alike local concoction that has the unfortunate effect of sending blood pressure vertical.
The story is fiction, but what's not made up is the very serious matter of counterfeit medicine - bogus drugs. Whenever there's enough demand for a particular product, there will be somebody who'll fill that demand with something that looks like the real thing, but is absolutely not. This is a huge problem for legitimate pharmaceutical firms and patients alike. At best, the fake has no effect at all; at worst it can kill you.
Discussing the scope of the problem and some of the measures being taken to suppress the counterfeit trade are two of the top experts in the world today:
• Anne-Lise Sauterey, Regional Coordinator for the Observatory of Illicit Trafficking under the auspices of the French Ministry of Foreign Affairs' Project FSP Mekong, who will discuss the multiple impacts of counterfeit medicines and today's most effective strategies to fight the problem, as well as describing a multi-dimensional model of how international agencies and authorities are working to eradicate bogus drugs in the Mekong region; and
• Scott Davis, senior director for Pfizer Global Security, Asia-Pacific, fresh from an appearance on the BBC's Asia Business Report, who will demonstrate the worldwide scope of the problem, and show real-life footage of actual raids on counterfeit drug manufacturing facilities.
